BrightGene Bio-Medical Technology Co., Ltd.: Obesity trials

The registry lists 11 Obesity studies with BrightGene Bio-Medical Technology Co., Ltd. as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 8Phase 2 2Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Bioequivalence Study of BGM0504 InjectionCompletedNCT07382908Phase 1
• A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese ParticipantsCompletedNCT07294235Phase 1
• A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese SubjectsCompletedNCT07239973Phase 1
• Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and WomenActive, not recruitingNCT07224399Phase 1
• Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult SubjectsCompletedNCT07166081Phase 1
• A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese SubjectsCompletedNCT06973681Phase 2
• A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal FunctionCompletedNCT06929156Phase 1
• A Study of BGM0504 in Overweight or Obese ParticipantsCompletedNCT06920056Phase 1
• A Study of BGM0504 in Participants With ObesityCompletedNCT06911203Phase 2
• Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult SubjectsCompletedNCT06714955Phase 1
• A Study of BGM0504 Injection in Participants With Obesity or OverweightCompletedNCT06704581Phase 3